b) a naturally-occurring amino acid sequence having at least [90] 95% sequence identity to the sequence of SEQ ID NO:1, wherein said amino acid sequence encodes a polypeptide whose expression is upregulated by TCDD,

c) a biologically-active fragment of the amino acid sequence of SEQ ID NO:1, wherein said fragment encodes a polypeptide whose expression is upregulated by TCDD, and

D1 cont

d) an [immunogenic] immunologically active fragment of the amino acid sequence of SEQ ID NO:1 wherein said fragment generates an antibody that specifically binds to the polypeptide encoded by SEQ ID NO:1.

19. (Reiterated.) An isolated polypeptide of claim 18, having a sequence of SEQ ID NO:1.

20. (Reiterated.) An isolated polynucleotide encoding a polypeptide of claim 18.

21. (Reiterated.) An isolated polynucleotide encoding a polypeptide of claim 19.

22. (Reiterated.) An isolated polynucleotide of claim 21, having a sequence of SEQ ID NO:2.

23. (Reiterated.) An expression vector comprising a promoter sequence operably linked to a polynucleotide of claim 20.

24. (Reiterated.) A host cell transformed with a recombinant polynucleotide of claim 23.

25. (Reiterated.) A method for producing a polypeptide of claim 18, the method comprising:

a) culturing a host cell under conditions suitable for expression of the polypeptide, wherein said host cell is transformed with an expression vector, and said expression vector comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 18, and

b) recovering the polypeptide so expressed.

26. (Reiterated.) A method of claim 25, wherein the polypeptide has the sequence of SEQ ID NO:1.

27. (Reiterated.) An isolated polynucleotide comprising a sequence selected from the group consisting of:

a) a polynucleotide sequence of SEQ ID NO:2,

b) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,

c) a polynucleotide sequence complementary to a),

d) a polynucleotide sequence complementary to b) and

e) a ribonucleotide equivalent of a)-d).

28. (Reiterated.) An isolated polynucleotide comprising at least 60 contiguous nucleic acids of claim 27.

29. (Reiterated.) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 27, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

30. (Reiterated.) A method of claim 29, wherein the probe comprises at least 60 contiguous nucleotides.

31. (Reiterated.) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 27, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

32. (Reiterated.) An isolated antibody which specifically binds to a polypeptide of claim 18.

33. (Reiterated.) A pharmaceutical composition comprising an effective amount of a polypeptide of claim 18 and a pharmaceutically acceptable excipient.

34. (Reiterated.) A pharmaceutical composition of claim 34, wherein the polypeptide has the sequence of SEQ ID NO:1.

35. (Reiterated.) A method for treating a disorder which is associated with decreased expression of the polypeptide of claim 18 comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition comprising said polypeptide and a pharmaceutically acceptable excipient.

36. (Reiterated.) A purified agonist which specifically binds to and modulates the activity of the polypeptide of claim 18.

37. (Reiterated.) A purified antagonist which specifically binds to and inhibits the activity of the polypeptide of claim 18.

38. (Reiterated.) A pharmaceutical composition comprising the antagonist of claim 37 in conjunction with a suitable pharmaceutical carrier.